Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16760957 | 0.84 | SIGMAR1 (0.56) | KMT2AALDH1A1NCF1 | |
| SCHEMBL17175745 | 0.79 | MEN1 (0.70) | KMT2AMEN1PKMKDM4EALDH1A1 | |
| SCHEMBL30469295 | 0.77 | PRMT6 (0.68) | KDM4EALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13242846 | 0.77 | PRMT6 (0.62) | KDM4EALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL833409 | 0.77 | PRMT6 (0.68) | KDM4EALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15708753 | 0.77 | ALDH1A1 (0.67) | KMT2AMEN1PKMKDM4EALDH1A1 | |
| SCHEMBL264786 | 0.76 | NCF1 (0.71) | KMT2AMEN1KDM4EALDH1A1NCF1 | |
| SCHEMBL30704912 | 0.76 | NCF1 (0.71) | KMT2AMEN1KDM4EALDH1A1NCF1 | |
| SCHEMBL374345 | 0.76 | ALDH1A1 (0.59) | KMT2AMEN1KDM4EALDH1A1NCF1 | |
| SCHEMBL29715963 | 0.76 | LMNA (0.64) | NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190099453-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099453-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | PYGL, HNF4A, ATF1 | KMT2A 2105/4885MEN1 3939/4885PKM 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.